Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.

MLA

Tiseo, Giusy, et al. “Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.” Infectious Diseases and Therapy, vol. 12, no. 1, Jan. 2023, pp. 257–71. EBSCOhost, https://doi.org/10.1007/s40121-022-00729-2.

APA

Tiseo, G., Barbieri, C., Galfo, V., Occhineri, S., Matucci, T., Almerigogna, F., Kalo, J., Sponga, P., Cesaretti, M., Marchetti, G., Forniti, A., Caroselli, C., Ferranti, S., Pogliaghi, M., Polidori, M., Fabiani, S., Verdenelli, S., Tagliaferri, E., Riccardi, N., … Falcone, M. (2023). Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. Infectious Diseases and Therapy, 12(1), 257–271. https://doi.org/10.1007/s40121-022-00729-2

Chicago

Tiseo, Giusy, Chiara Barbieri, Valentina Galfo, Sara Occhineri, Tommaso Matucci, Francesco Almerigogna, Jona Kalo, et al. 2023. “Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.” Infectious Diseases and Therapy 12 (1): 257–71. doi:10.1007/s40121-022-00729-2.